¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hormone, growth"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • local hormone
    ±¹¼ÒÈ£¸£¸ó
  • luteal hormone
    Ȳ(»ö)üȣ¸£¸ó
  • luteinizing hormone
    Ȳ(»ö)üÇü¼ºÈ£¸£¸ó
  • luteinizing hormone releasing factor
    Ȳ(»ö)üÇü¼ºÈ£¸£¸óºÐºñÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    Ȳ(»ö)üÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • luteotropic hormone
    Ȳ(»ö)üÀÚ±ØÈ£¸£¸ó
  • lactogenic hormone
    Á¥ºÐºñÈ£¸£¸ó, À¯ÁóºÐºñÈ£¸£¸ó
  • male hormone
    ³²¼ºÈ£¸£¸ó
  • melanocyte-stimulating hormone
    ¸á¶ó´Ñ¼¼Æ÷ÀÚ±ØÈ£¸£¸ó
  • neurohypophysial hormone
    ½Å°æ³úÇϼöüȣ¸£¸ó
  • pituitary hormone
    ³úÇϼöüȣ¸£¸ó
  • placental hormone
    ŹÝÈ£¸£¸ó
  • parathyroid hormone
    ºÎ°©»ó»ùÈ£¸£¸ó, ºÎ°©»ó¼±È£¸£¸ó
  • releasing hormone
    À¯¸®È£¸£¸ó, ¹æÃâÈ£¸£¸ó
  • somatotropic hormone
    ¼ºÀåÀÚ±ØÈ£¸£¸ó
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hypothalamic inhibitory hormone
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • hypothalamic releasing hormone
    ½Ã»óÇϺκкñÈ£¸£¸ó
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
  • interstitial cell-stimulating hormone
    »çÀÌÁú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó
  • lactogenic hormone
    (¢¡prolactin) ÇÁ·Î¶ôƾ, Á¥ºÐºñÈ£¸£¸ó
  • local hormone
    ±¹¼ÒÈ£¸£¸ó
  • luteal hormone
    Ȳüȣ¸£¸ó
  • luteinizing hormone
    ȲüÇü¼ºÈ£¸£¸ó
  • luteotropic hormone
    ȲüÀÚ±ØÈ£¸£¸ó
  • male hormone
    ³²¼ºÈ£¸£¸ó
  • melanocyte-stimulating hormone
    ¸á¶ó´Ñ¼¼Æ÷ÀÚ±ØÈ£¸£¸ó
  • melanophore expanding hormone
    ¸á¶ó´Ñº¸À¯¼¼Æ÷Áõ·®È£¸£¸ó
  • molting hormone
    Åа¥ÀÌÈ£¸£¸ó
  • neurohypophysial hormone
    ½Å°æ³úÇϼöüȣ¸£¸ó
  • ovulation inducing hormone
    ¹è¶õÀ¯µµÈ£¸£¸ó
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Hyperglycemic hormone
    Ç÷´ç»ó½Â(úìÓØß¾ã°)È£¸£¸ó
  • ICSH = interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±Ø(Êàòõá¬øàí©Ð½)È£¸£¸ó.
  • ICSH=£¾interstitial cell stimulating hormone
    °£Áú¼¼Æ÷ÀÚ±ØÈ£¸£¸ó.
  • LH = luteinizing hormone
    Ȳüȭ(üÜô÷ûù)È£¸£¸ó.
  • LH= luteinizing hormone
    Ȳüȭȣ¸£¸ó.
  • MEH=£¾melanophore expanding hormone
    ¸á¶ó´Ñ º¸À¯¼¼Æ÷ Áõ·®È£¸£¸ó.
  • TRH => thyrotrophin releasing hormone
    °©»ó¼±ÀÚ±ØÈ£¸£¸ó ºÐºñÈ£¸£¸ó
  • TSH=£¾thyroid stimulating hormone
    °©»ó¼±ÀÚ±ØÈ£¸£¸ó
  • TSH=£¾thyroid stimulating hormone
    °©»ó¼±ÀÚ±ØÈ£¸£¸ó.
  • adrenal corticotropic hormone =ACTH
    ºÎ½ÅÇÇÁúÀÚ±Ø(¡­ô§Ð½)È£¸£¸ó
  • androgenic hormone
    ³²¼ºÈ£¸£¸ó
  • anterior lobe hormone
    ÇϼöüÀü¿±(ù»á÷ô÷îñç¨)È£¸£¸ó.
  • anterior pituitary-like hormone =APLH
    ÇϼöüÀü¿±¾çÈ£¸£¸ó.
  • antidiuretic hormone
    Ç×ÀÌ´¢(ù÷ì¦Òã) È£¸£¸ó
  • antidiuretic hormone
    Ç×ÀÌ´¢È£¸£¸ó(¡­××Òã¡­)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • curve, single-step growth
    ÀÏȸÁõ½Ä°î¼±
  • cycle, growth
    Áõ½ÄÁÖ±â
  • developmental disease =growth abnor mal ity
    ¹ß´ÞÀÌ»ó(¡­ì¶ßÈ).
  • economic growth
    °æÁ¦¼ºÀå.
  • endothelial cell growth factor
    ³»ÇǼ¼Æ÷ Áõ½ÄÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ(øúù«à÷íþì×í­)
  • epidermal growth factor
    Ç¥ÇǼºÀå ÀÎÀÚ(¡­à÷íþ ì×í­)
  • epidermal growth factor (EGF)
    ÇǺÎÁõ½ÄÀÎÀÚ
  • epidermal growth factor = EGF
    Ç¥ÇÇ ¼ºÀå ÀÎÀÚ
  • epidermoid growth factor
    Ç¥ÇÇ¾ç ¼ºÀåÀÎÀÚ(¡­à÷íþì×í­)
  • essential growth factor
    ÇʼöÁõ½ÄÀÎÀÚ
  • excessive growth
    ¼ºÀå°úµµ
  • exponential growth
    Áö¼öÁõ½Ä.
  • exponential growth phase
    Áö¼öÁõ½Ä±â(ÊÙÌ¡ËàË»).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • linear growth
    ¼±Çü¼ºÀå(àÊû¡à÷íþ)
  • logarithmic growth
    ´ë¼ö Áõ½Ä(ÓÛâ¦ñòãÖ)
  • molar growth yield
    ¸ô¼ºÀå¼öÀ²(à÷íþâ¥ëÏ)
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ(ãêÌèà÷íþì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡(úìá³÷ùë¦ÕÎ) ¼ºÀåÀÎÀÚ(à÷íþì×í­)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • step-growth polymer
    ´Ü°è¼ºÀå ÁßÇÕü(Ó«Í­à÷íþñìùêô÷)
  • synchronous growth
    µ¿±â¼ºÀå (ÔÒÑ¢à÷íþ)
  • tail growth
    ²¿¸®¼ºÀå (à÷íþ)
  • tailward growth
    ²¿¸®¹æÇâ ¼ºÀå (à÷íþ)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • unbalanced growth
    ºÒ±ÕÇü(ÝÕгû¬) ¼ºÀå (à÷íþ)
  • adipokinetic hormone
    Áö¹æµ¿¿ø(ò·Û²ÔÑê¬)È£¸£¸ó
  • adrenal cortical hormone
    ºÎ½ÅÇÇÁú(Üùãìù«òõ)È£¸£¸ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
GH-RIH growth hormone-release inhibiting hormone
GRH growth hormone-releasing hormone
hGRH human growth hormone-releasing hormone
LHRH Luteinizing Hormone Releasing Hormone
  ? GnRH; Gonadotropin Releasing Hormone
&nbs...
FSH/LR-RH follicle-stimulating hormone and luteinizing hormone releasing hormone
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
LHRHa leuteinizing hormone-releasing hormone analogue
PTH/PTHrP Parathyroid hormone/parathyroid-hormone-related peptide
GnRH gonadotropin hormone releasing hormone
HGH 125I-human growth hormone
bGH Bovine growth hormone
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • total growth
    ÃÑ Áõ½Ä·®
  • tumor growth
    Á¾¾ç ¼ºÀå
  • uncontrolled destructive growth
    ºñÁ¶Àý¼º ÆÄ±«¼º ¼ºÀå
    ÀÎÀ§ÀûÀ¸·Î Á¶ÀÛÀÌ ¾ÈµÇ°í ÀÚ¶ó¸é¼­ ÆÄ±«Àû ¼ºÁúÀ» Áö´Ï´Â °Í.
  • vascular endothelial growth factor
    ¸Æ°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ, Ç÷°ü ³»ÇǼ¼Æ÷ ¼ºÀå ÀÎÀÚ
  • vertical growth
    ¼öÁ÷ ¼ºÀå
  • adrenal corticotropic hormone
    ºÎ½Å ÇÇÁú ÀÚ±Ø È£¸£¸ó
  • adrenocorticotrophic hormone
    ºÎ½Å ÇÇÁú ÀÚ±Ø È£¸£¸ó
    ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸ó. ºÎ½Å ÇÇÁú¿¡ ÀÛ¿ëÇØ¼­ ¼± ¼¼Æ÷ÀÇ Áõ½Ä, È£¸£¸óÀÇ ÇÕ¼º°ú ºÐºñ¸¦ ÃËÁøÇÑ´Ù. »ç¶÷ÀÇ °æ¿ì, 39°³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î Çü¼ºµÇ´Â Æú¸® ÆéƼµå·Î È­ÇÐÀûÀ¸·Î´Â ´Ü¹éÁúÀÌ´Ù. »ýü°¡ ½ºÆ®·¹½º¸¦ ¹ÞÀ¸¸é ÁßÃ߽Űæ°è¸¦ ÅëÇØ ÀÌ È£¸£¸ó ºÐºñ°¡ ÃËÁøµÇ¾î ºÎ½Å ÇÇÁú È£¸£¸óÀÌ ´Ù·®À¸·Î °ø±ÞµÈ´Ù. ACTH´Â ¶Ç ÄÚ¸£Æ¼¼Õ µî ºÎ½Å ÇÇÁú È£¸£¸óÀ» ¸Å°³·Î Çϸç, °áÇÕÁ¶Á÷ÀÇ ´ë»ç ÀÌ»óÀ» Á¶Á¤ÇÏ°í ·ù¸ÓƼÁò¼º ¶Ç´Â ·ù¸ÓƼÁò Áúȯ¿¡ È¿°ú°¡ ÀÖ´Ù.
  • adrenocorticotropic hormone
    ºÎ½Å ÇÇÁú ÀÚ±Ø È£¸£¸ó
    ³úÇϼöü Àü¿±¿¡¼­ »ý¼º, ºÐºñµÇ¾î ºÎ½Å ÇÇÁú¿¡ ÀÛ¿ëÇØ¼­ ÄÚÆ¼¼Ö ¹× ÄÚÆ¼ÄÚ½ºÅ×·ÐÀÇ ºÐºñ¸¦ ÃËÁøÇϴ ȣ¸£¸ó. ½ºÆ®·¹½º ½Ã¿¡ ½Ã»óÇϺο¡ ÈïºÐÀÌ ÀϾ Á¤Áß À¶±â¿¡¼­ ºÎ½Å ÇÇÁú ÀÚ±Ø È£¸£¸ó ¹æÃâ ÀÎÀÚ°¡ ¸ÕÀú ºÐºñµÇ¸é À̰ÍÀÌ ³úÇϼöü ¹®¸ÆÀ» ÅëÇØ¼­ ³úÇϼöü Àü¿±¿¡ µµ´ÞÇÏ¿© °Å±â¿¡¼­ ACTHÀÇ »ý¼º ¹× ºÐºñ¸¦ ÃËÁøÇÑ´Ù.
  • adrenomedullary hormone
    ºÎ½Å ¼öÁú È£¸£¸ó
  • antidiuretic hormone
    Ç×ÀÌ´¢ È£¸£¸ó
    ADH-vaso
  • chromatophoriotropic hormone
    Çâ»ö¼Ò º¸À¯ ¼¼Æ÷ È£¸£¸ó
  • cortical hormone
    ÇÇÁú È£¸£¸ó
  • corticosteroid hormone
    ÄÚÆ¼ÄÚ½ºÅ×·ÎÀ̵å È£¸£¸ó
  • female hormone
    ¿©¼º È£¸£¸ó
    ôÃß µ¿¹° ¾ÏÄÆÀÇ ³­¼Ò¿¡¼­ ºÐºñµÇ¾î ¼º±âÀÇ ¹ßÀ°°ú »ý½Ä±â´É Á¶Àý µî¿¡ ÀÛ¿ëÇÏ´Â ¼º È£¸£¸ó. ³­¼Ò È£¸£¸óÀ̶ó°íµµ ÇÑ´Ù. ¿©Æ÷¿¡¼­ ³ª¿À´Â ¿©Æ÷ È£¸£¸ó°ú Ȳü¿¡¼­ ³ª¿À´Â Ȳü È£¸£¸óÀÌ ÀÖ´Ù. ÀÇ¾à ¹æ¸é¿¡¼­ º¸Åë ¿©¼º È£¸£¸óÀ̶ó°í ÇÒ ¶§´Â ¿©Æ÷ È£¸£¸óÀ» ¸»ÇÑ´Ù. ¿©Æ÷ È£¸£¸óÀº ¹ßÁ¤ È£¸£¸óÀ¸·Î ¿©¼º »ý½Ä±âÀÇ ¹ßÀ°À» ÃËÁøÇÏ¿© ¿©¼º´Ù¿òÀ» ÁõÁø½ÃŲ´Ù. Ȳü È£¸£¸óÀº ¹ßÁ¤ È£¸£¸ó¿¡ ±æÇ×ÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¹ßÁ¤À» ¾ïÁ¦ÇÑ´Ù. À̵é È£¸£¸óÁ¦ÀÇ »ç¿ëÀº ÀÎü¿¡ ÀÌ»óÇÑ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ¼ö°¡ ÀÖÀ¸¹Ç·Î ±× »ç¿ëÀº ¹Ýµå½Ã Àü¹® ÀÇ»çÀÇ Áö½Ã¿¡ µû¶ó¾ß ÇÑ´Ù. ¹ßÁ¤ È£¸£¸óÀÇ ÀÛ¿ëÀ» °¡Áø ¹°ÁúÀ» ÃÑÄªÇØ¼­ ¿¡½ºÆ®·Î°Õ
  • follicle stimulating hormone releasing factor
    ³­Æ÷ ÀÚ±Ø È£¸£¸ó ¹æÃâ ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
receptors, fibroblast growth factor Specific molecular sites or structures on cell membranes that react with fibroblast growth factors (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.
(12 Dec 1998)
receptors, growth factor Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells.
(12 Dec 1998)
receptors, insulin-like-growth factor I Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity.
(12 Dec 1998)
receptors, insulin-like-growth-factor II Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity.
(12 Dec 1998)
receptors, nerve growth factor Cell surface receptors that bind nerve growth factor (ngf) and trigger intracellular changes influencing the behaviour of cells. Nerve growth factor receptors mediate the effects of nerve growth factor on the survival and growth of neurons.
(12 Dec 1998)
receptors, platelet-derived growth factor Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain.
(12 Dec 1998)
receptors, transforming growth factor beta Cell-surface proteins that bind transforming growth factor beta and trigger changes influencing the behaviour of cells. Two types of transforming growth factor receptors have been recognised. They differ in affinity for different members of the transforming growth factor beta family and in cellular mechanisms of action. Transforming growth factor alpha binds to the same receptors as epidermal growth factor (see receptors, epidermal growth factor-urogastrone).
(12 Dec 1998)
vertical growth phase Spread of melanoma cells from the epidermis into the dermis and later the subcutis, from which site metastasis may take place.
(05 Mar 2000)
cell growth <cell biology> Usually used to mean increase in the size of a population of cells though strictly should be reserved for an increase in cytoplasmic volume of an individual cell.
(26 Mar 1998)
melanoma growth stimulatory activity Cytokine of the C X C subfamily. Potent mitogen. Activates and is chemotactic for, neutrophils.
(18 Nov 1997)
personal growth laboratory A sensitivity training setting in which the primary emphasis is on each participant's potentialities for creativity, empathy, and leadership.
See: sensitivity training group.
(05 Mar 2000)
growth 1. The process of growing; the gradual increase of an animal or a vegetable body; the development from a seed, germ, or root, to full size or maturity; increase in size, number, frequency, strength, etc.; augmentation; advancement; production; prevalence or influence; as, the growth of trade; the growth of power; the growth of intemperance. Idle weeds are fast in growth.
2. That which has grown or is growing; anything produced; product; consequence; effect; result. "Nature multiplies her fertile growth." (Milton)
Origin: Icel. Gror, gri. See Grow.
Source: Websters Dictionary
(01 Mar 1998)
growth and embryonic development Developmental processes from cell division to embryogenesis to postnatal growth and maturity.
(12 Dec 1998)
growth arrest lines Dense lines parallel to the growth plates of long bones on radiographs, representing temporary slowing or cessation of longitudinal growth.
Synonym: Harris' lines.
(05 Mar 2000)
growth associated proteins <growth factor> Group of developmentally regulated polypeptides thought to be critical for the formation of neural circuitry. The acidic membrane phosphoprotein GAP 43 is synthesised and transported down regenerating and developing axons, pp46 localised in growth cone membranes during embryogenesis, B 50 in mature presynaptic membranes in the regulation of phosphotidylinositol turnover and F1 in the hippocampus during long-term potentiation, are now all known to be the same protein.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á